|
Aug 11
|
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
|
|
Aug 6
|
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 6
|
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
|
|
Aug 4
|
MaxCyte Signs Platform License Agreement with Adicet Bio
|
|
Jul 31
|
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
|
|
Jul 9
|
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
|
|
Jul 1
|
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan
|
|
May 8
|
MaxCyte Inc (MXCT) Q1 2025 Earnings Call Highlights: Strong Revenue Alignment Amidst Growth ...
|
|
May 7
|
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
|
|
Jan 1
|
MaxCyte, Inc.'s (LON:MXCT) Intrinsic Value Is Potentially 72% Above Its Share Price
|
|
Nov 13
|
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
|
|
Oct 10
|
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
|
|
Oct 9
|
MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges
|
|
Jul 17
|
MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable
|
|
May 29
|
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
|
|
May 23
|
With 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional owners
|
|
May 12
|
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Q1 2024 MaxCyte Inc Earnings Call
|
|
May 8
|
MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...
|
|
May 7
|
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
|